21 December 2021
Jenner researchers have published a pre-print on how new adenovirus-based vaccines could be produced at large-scale within 100 days of identification of a new virus or variant. They also report an improved manufacturing method which could enable production of 1 billion doses per month. The paper is being submitted to BioRxiv and a peer-reviewed journal, and is temporarily available here:
15 December 2021
The Poonawalla Vaccines Research Building is to be established at Oxford University's Old Road Campus following a £50m funding commitment from Serum Life Sciences, a subsidiary of Serum Institute of India. The building will be a new home for the Jenner Institute. The donation will be the University’s largest ever gift for vaccines research.
10 December 2021
In this open call TRANSVAC2 offers free advanced courses on Adjuvants and Vaccine Formulations, Statistics of vaccine evaluation, and Regulatory aspects of vaccine development. Apply until December 15th at www.transvac.org.
7 December 2021
Featuring notable speakers from business, science or politics since 1972, Prof. Gilbert delivered the 44th Richard Dimbleby Lecture, held this year at Oxford's Blavatnik School of Government. Dame Sarah Gilbert is the Saïd Professor of Vaccinology, at the Jenner Institute & Nuffield Department of Clinical Medicine. The lecture is available (in the UK) via the BBC iPlayer.
1 December 2021
The Globally Relevant AIDS Vaccine Europe-Africa Trials Partnership (GREAT) is pleased to announce the completion of recruitment of volunteers for the Phase I HIV-CORE 006 HIV vaccine clinical trial at four sites in Kenya, Uganda and Zambia. Enrolment of the final participants took place today at the KEMRI-Wellcome Trust Research Programme in Kilifi, Kenya, on World AIDS Day.
30 November 2021
The 2021 Royal Society Africa Prize Seminar will be given by Professor George Warimwe, Jenner Investigator. More than 70% of these infectious diseases are zoonotic, with some causing illness and death in humans as well as the animal host. Professor Warimwe will discuss his ‘one health' approach to developing a single Rift Valley Fever vaccine suitable for humans and livestock. The lecture will take place online 2 December at 6.30pm GMT.
29 November 2021
The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award 2021.
16 November 2021
University researchers reveal invention of simple manufacturing method which has enabled rapid scale up of vaccine manufacturing in 15 countries around the world, reaching people across seven continents. The approach provides a template for faster and more equitable supply of other vaccines.
16 November 2021
The University of Oxford is to benefit from $2 million (£1.49 million) in funding from the Chan Zuckerberg Initiative (CZI) to investigate how our ancestry and diversity influence the way that vaccines work in our cells. The Oxford team includes a number of investigators across several departments including the Jenner Institute. Find out more: (https://www.ox.ac.uk/news/2021-11-16-2m-fund-awarded-oxford-s-single-cell-ancestry-vaccine-research)
11 November 2021
The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations having already taken place.
4 October 2021
The Oxfordshire Local Enterprise Partnership (OxLEP) has secured funding to support the University of Oxford’s Clinical BioManufacturing Facility (CBF) – a UK leader in the production of vaccines for early phase clinical trials, including the Oxford-AstraZeneca vaccine.
3 September 2021
Research from Jenner Institute and Ludwig Institute for Cancer Research has shown the technology behind the Oxford-AstraZeneca COVID-19 vaccine has potential in treating cancer. When tested in mice, the cancer vaccine increased levels of anti-tumour T cells infiltrating tumours and improved efficacy of cancer immunotherapy. Compared to immunotherapy alone, the combination with the vaccine showed a greater reduction in tumour size and improved survival of the mice.
23 August 2021
The Royal Society Africa Prize 2021 is awarded to Professor George Warimwe, Jenner Investigator, for his work on zoonoses vaccine development, capacity building in Africa, and his innovative research proposal. Professor Warimwe will be awarded a medal and a grant of £15,000 towards his research project at a symposium to be held at a future date.
20 August 2021
The Oxford-run VALIDATE Network, co-directed by Jenner Investigator Prof Helen McShane, has received $1.5 million in funding for its tuberculosis vaccine work from the Bill & Melinda Gates Foundation. An effective vaccine for TB is one of the primary goals of the VALIDATE Network which aims to accelerate vaccine development for complex intracellular pathogens that are often neglected.
6 August 2021
As the University was planning the first clinical trials for the COVID-19 vaccine, some began to wonder how to supply the vaccine to the world - if it worked. Although Oxford had the capacity to develop a COVID-19 vaccine, and clinical trials might take only a few months, manufacturing ‘at pandemic scale’ would take much longer. A group of University scientists had, however, worked on the problem for some time.
4 August 2021
The course provides teaching in human and veterinary vaccinology by an exceptional faculty of academic and industrial speakers, with an emphasis on strengthening vaccine development and manufacturing autonomy in Africa. The course alternates between East and West Africa. In 2021, participation is for attendees working or studying in East Africa. Applications close 31 August.
3 August 2021
Professor Tomas Hanke, Professor of Vaccine Immunology at the Jenner Institute, and lead researcher on the trial, said: ‘This highly rational, bioinformatics-assisted, vaccine design addresses the enormous variability of HIV-1 - one of the greatest challenges to the development of an effective vaccine against HIV/AIDS.’
29 July 2021
The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.
16 July 2021
Adenovirus vaccine vectors, such as the ChAdOx1 nCov-19 construct which has risen to prominence as a major vaccine for COVID-19, may generate robust long-term immune system responses, according to scientists from the Universities of Oxford and the Cantonal Hospital St.Gallen, Switzerland.
5 July 2021
Vaccinations started today of a novel HIV vaccine candidate as part of a Phase I clinical trial in the UK. Professor Tomáš Hanke, Professor of Vaccine Immunology at the Jenner Institute and lead researcher on the trial, said: ‘An effective HIV vaccine has been elusive for 40 years. This trial is the first in a series of evaluations of this novel vaccine strategy in both HIV-negative individuals for prevention and in people living with HIV for cure.’